Oncology

Evolving Considerations in the Treatment and Management of Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2023, it is expected that there will be approximately 238,340 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there will be an estimated 127,070 deaths from lung cancer in 2023, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets, especially around KRAS mutation–positive NSCLC. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Healthcare professionals (HCPs) need to be aware of information regarding tumor-specific diagnosis, expanding treatment options, and supporting data to maximize the care of their patients. Additionally, more agents have recently been approved for patients with KRAS mutation–positive NSCLC and these options have shown the ability to help increase prognosis and quality of life in NSCLC patients. With so many effective treatment options becoming available, it is critical to inform physician medical directors, oncologists and nurses about these agents, and strategies to effectively manage NSCLC patients.
Physician, Nursing and CMCN credits valid to August 1, 2024

Best Practices in the Treatment and Management of Acute Myeloid Leukemia (AML): Managed Care Decision Making in an Evolving Landscape

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The American Cancer Society estimates that there were approximately 20,050 new cases of AML and 11,540 deaths from AML in the United States in 2022. The five-year survival rate has not improved in older patients despite 40 years of research. Fortunately for patients with AML, many new treatments are now here. New options, which have the ability to target certain types of mutations, have been approved in AML for the first time since 1990. With so many new options becoming available in the past few years, the treatment paradigm in AML, especially in relapsed or refractory and high-risk disease and in maintenance settings, has drastically changed. With that change comes a knowledge gap among physician medical directors, oncologists, practicing physicians and nurses. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the AML patient population.
Physician, Nursing and CMCN credits valid to August 1, 2024

Changing the Treatment Landscape for Prostate Cancer:
Moving Towards Improved Outcomes

Prostate cancer is the most diagnosed non-cutaneous cancer in men in the United States (US) and remains the second leading cause of cancer deaths among American men, with an estimated 248,530 new cases diagnosed last year. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. About 40 percent of these patients have prostate cancer that is also associated with a rising prostate-specific antigen (PSA) level that has not spread to other parts of the body. The danger that can occur, if not caught early, is that 33% of those men could have the cancer spread to other parts of the body. With guidelines continuing to be updated, the novel insights in the current and emerging therapeutic agents hope to continue to improve patient prognosis and quality of life by delaying metastatic spread and the need for highly toxic chemotherapeutic agents. Advances in the past few years have resulted in the investigations of several novel targeted therapies, including androgen receptor inhibitor (ARI) targeting agents, antineoplastic agent and gonadotropin releasing hormone agonist, tyrosine kinase inhibitors (TKIs), antiangiogenic agents, endothelin receptor antagonists, anti-apoptotic protein inhibitors, and PARP-1 inhibitors. This session will provide participants with education on the advances in the treatment and management of prostate cancer. In the last few years, advances in the treatment of prostate cancer have greatly improved with new updates in current and emerging treatments.
Physician, Nursing and CMCN credits valid to March 1, 2024

Patient-Focused Treatment Decisions in the Management of Ovarian Cancer: Managed Care Considerations in the Evolving Role of PARPi

There will be an estimated 21,410 new cases of ovarian cancer this year in the United States, and an estimated 13,770 deaths due to ovarian cancer in the US, according to the American Cancer Society. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Additionally, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. It is important for medical directors, oncologists, and nurses who manage ovarian cancer patient populations to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application.
Physician, Nursing and CMCN credits valid to March 1, 2024

Recent Therapeutic Advances in the Management of Metastatic Bladder Cancer: Managed Care Perspectives on Immunotherapy in the First Line Setting is a two-part webinar series

Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. According to the American Cancer Society, there were 81,180 new cases of bladder cancer and 17,100 deaths in the United States in 2022. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. As the role of the immune system in oncogenesis and therapy has become clearer across cancer types, new approaches emerged with important benefits in metastatic bladder cancer. In particular, immune checkpoint inhibitors have changed the treatment paradigm, as recent data has shown that immunotherapy greatly improves outcomes, especially with maintenance therapy in the first line setting. This program will provide attendees with the latest on the first line maintenance setting and provide updated education on differences in pharmacology, efficacy, and safety of these agents and roles that managed care professionals can play to drive appropriate access to and use of immune checkpoint inhibitors in various settings in locally advanced or metastatic bladder cancer to optimize clinical and economic outcomes for patients.
Physician, Nursing and CMCN credits valid to March 1, 2024

Innovative Approaches in the Management of Advanced Renal Cell Carcinoma (RCC): Managed Care Considerations on Targeted Therapy and Immunotherapy Combinations

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. In 2022, it is estimated that there will be approximately 76,080 new cases of kidney cancer, and about 13,780 people will die from the disease. Approximately 16% of patients with RCC will have metastases at diagnosis, and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year survival rate ranging from 5% to 12%, the prognosis for these patients is poor. Fortunately for patients with advanced RCC, several new treatments, including targeted therapies and immunotherapies, have recently become available giving clinicians new options to improve patient outcomes and quality of life. Additionally, new combination regimens comprised of multiple receptor tyrosine kinase inhibitors and anti-PD-1 immunotherapies have shown improved efficacy and safety in clinical trials. With so many new options becoming available for the healthcare community, clinicians are struggling to stay abreast of all the changes in advanced RCC treatment. It is critical that medical directors, oncologists, nurses and other healthcare professionals are updated on these emerging options and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.
Physician, Nursing and CMCN credits valid to March 1, 2024

New Horizons in the Treatment and Management of Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2021, it was expected that there were about 228,820 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 135,720 deaths from lung cancer in 2021, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Healthcare professionals (HCPs) need to be aware of information regarding tumor-specific diagnosis, expanding treatment options, and supporting data to maximize the care of their patients. With so many effective treatment options becoming available, it is critical to inform medical directors, oncologists and nurses about these agents, and strategies to effectively manage NSCLC patients.
Physician, Nursing and CMCN credits valid to March 1, 2024

Evolving Considerations in the Management of Chronic Lymphocytic Leukemia (CLL): Optimizing Clinical and Economic Outcomes with BTK Inhibitors

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects older adults. CLL is the most common type of leukemia in adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In 2022, it is expected that there will be 20,160 new cases of CLL and about 4,410 deaths, which represents an increase in both numbers. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Fortunately for patients with CLL, several new treatments have recently become available giving clinicians many new options to improve patient outcomes with these new treatments and strategies. New combination regimens have recently become available that have shown the ability to greatly improve outcomes in previously untreated CLL. This activity focuses on these evolving options, outlines how to incorporate quality measures for the diagnosis and management of CLL, and describes how to apply evidence-based data to select appropriate treatment regimens and manage toxicities.
Physician, Nursing and CMCN credits valid to March 1, 2024

Navigating an Increasingly Complex Treatment Paradigm in the Management of Breast Cancer: Optimizing Clinical and Economic Outcomes with Targeted Therapy

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2022. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely, and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer
(MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with both early and advanced breast cancer, several new agents, including PARP inhibitors, have recently become available. They have shown the ability to improve safety and efficacy outcomes.
Physician, Nursing and CMCN credits valid to March 1, 2024

Best Practices in the Treatment and Management of Melanoma: Expert Strategies on Evolving Combinations for Optimized Patient Outcomes

Melanoma is the most serious type of skin cancer. It occurs in skins cells called melanocytes, and while it is predominantly found in the skin, it can occur in any area of the body that contains melanocytes. Melanoma will be found in approximately 106,110 people in the United States in 2022 according to the National Cancer Institute. While it is the least common amongst skin cancers, it is by far the deadliest, with 7,180 people expected to die in 2022. Both of those numbers have been rising in recent years. In the early stages of melanoma, prognosis is usually good for patients, but when the melanoma becomes metastatic and spreads to other areas of the body, prognosis is especially poor. Fortunately for patients with metastatic melanoma, and the physicians that treat them, significant progress has been made in the treatment of this deadly disease over the past few years, especially in the area of immunotherapies and novel combinations.
Physician, Nursing and CMCN credits valid to March 1, 2024

Managed Care Considerations in the Treatment and Management of Acute Myeloid Leukemia (AML): Optimizing Decision-Making Strategies for Improved Clinical and Economic Outcomes

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The American Cancer Society estimates that there were approximately 19,940 new cases of AML and 11,180 deaths from AML in the United States in 2021. The five-year survival rate has not improved in older patient’s despite of 40 years of research. Fortunately for patients with AML, many new treatments have recently been approved for use. These options, which are among the first new treatments in AML since 1990, have drastically changed the treatment paradigm. With that change comes a knowledge gap among physician medical directors, oncologists, practicing physicians and nurses. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm which will ultimately improve patient outcomes in the AML patient population.
Physician, Nursing and CMCN credits valid to March 1, 2024

Innovations in Prostate Cancer Management: Taking a Personalized Approach to Optimal Treatment

Patients with all stages of prostate cancer have many treatment options available to them, from front-line therapy to second-line therapy and beyond with both immunotherapy and chemotherapy as current options. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with prostate cancer have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer, identifying patients who have prostate cancer and preventing undertreatment. This marker is used for early diagnosis and monitoring for disease recurrence. PSA is the most common biochemical marker for prostate cancer and is used as a screening tool, although it remains prostate specific and not necessarily prostate cancer specific.
Physician, Nursing and CMCN credits valid to August 1, 2023

Managed Care Perspectives on the Treatment and Management of Ovarian Cancer: Optimizing Outcomes with PARP Inhibitors

Recent Advances in the Treatment and Management of Non-Small Cell Lung Cancer (NSCLC): Managed Care Perspectives for Improved Patient Outcomes

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it was expected that there were about 228,820 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 135,720 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Healthcare professionals (HCPs) need to be aware of information regarding tumor-specific diagnosis, expanding treatment options, and supporting data to maximize the care of their patients.
Physician, Nursing and CMCN credits valid to August 1, 2023

Evolving Treatment Strategies in the Management of Metastatic Melanoma: Optimizing Immunotherapy Approaches for Improved Outcomes

Melanoma is the most serious type of skin cancer. It occurs in skins cells called melanocytes, and while it is predominantly found in the skin, it can occur in any area of the body that contains melanocytes. Melanoma will be found in approximately 106,110 people in the United States in 2021 according to the
National Cancer Institute. While it is the least common amongst skin cancers, it is by far the deadliest,
with 7,180 people expected to die in 2021. Both of those numbers have been rising in recent years. In the
early stages of melanoma, prognosis is usually good for patients, but when the melanoma becomes metastatic and spreads to other areas of the body, prognosis is especially poor. Fortunately for patients
with metastatic melanoma, and the physicians that treat them, significant progress has been made in the
treatment of this deadly disease over the past 10 years, especially in the area of immunotherapies. With
several new therapy options and indications recently approved for patients, including as an adjuvant
treatment in melanoma, it is critical to educate medical directors, practicing physicians, nurses and other healthcare professionals on the recent updates in treatment options and guideline recommendations.
Physician, Nursing and CMCN credits valid to August 1, 2023

Innovative Approaches in the Management of Metastatic Breast Cancer: Managed Care Considerations on the Evolving Role of Targeted Therapy

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2022. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with advanced breast cancer, several new agents, including PARP inhibitors, have recently become available. They have shown the ability to improve safety and efficacy outcomes. With these options becoming available for the treatment of metastatic breast cancer, it is critical to provide medical directors, oncologists, practicing physicians and others on the interprofessional management team with updated clinical data and strategies on the changing treatment paradigm, with the ultimate goal of improving patient outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2023

Evolving Considerations in the Management of HER2-Positive Advanced Breast Cancer: Individualized Treatment for Improved Clinical and Economic Outcomes

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2021. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have extra copies of the gene that makes the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. Additionally, in the later stages of HER2+ disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the HER2+ metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. Treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life.
Physician, Nursing and CMCN credits valid to August 1, 2023

Patient-Focused Treatment Decisions in the Management of Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects older adults. CLL is the most common type of leukemia in adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In 2021, it is expected that there will be 21,250 new cases of CLL and about 4,320 deaths, which represents an increase in both numbers. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Fortunately for patients with CLL, several new treatments have recently become available, including BTK inhibitors, giving clinicians many new options to improve patient outcomes with these new treatments and strategies. Additionally, combination options with BTK inhibitors are undergoing late stage clinical trials and regulatory review, giving even more options for patients with CLL. This activity focuses on these evolving options, and their combinations, outlines how to incorporate quality measures for the diagnosis and management of CLL, and describes how to apply evidence-based data to select appropriate treatment regimens and manage toxicities. With the availability of new treatments, it is critical that medical directors, oncologists, nurses and other healthcare professionals are updated on these emerging options, guidelines and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2023

Navigating the Changing Landscape in the Treatment and Management of Acute Myeloid Leukemia (AML): Key Considerations in Managed Care Decision-Making

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The American Cancer Society estimates that there were approximately 19,940 new cases of AML and 11,180 deaths from AML in the United States in 2020. The five-year survival rate has not improved in older patients despite of 40 years of research. Fortunately for patients with AML, many new treatments have recently been approved for use. These options, which are among the first new treatments in AML since 1990, have begun to drastically change the treatment paradigm. With that change comes a knowledge gap among physician medical directors, oncologists, practicing physicians and nurses. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the AML patient population.
Physician, Nursing and CMCN credits valid to June 1, 2023

Realizing the Potential of CDK 4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: Managed Care Considerations on Recent Evidence in Real-World Practice

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. The incidence in women in the United States is 1 in 8 (about 13 percent). About 43,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. Fortunately for advanced breast cancer patients with HR+/HER2- advanced breast cancer, several new agents, including CDK 4/6 inhibitors, have changed the paradigm in the last 10 years, and recent real-world data has been released that shows the strong efficacy and safety of these options. With this new data becoming available, it is imperative to provide medical directors, oncologists, pharmacy directors, oncology case managers and others on the interprofessional management team with this new data and best practices on the evolving treatment paradigm, with the ultimate goal of optimizing access and improving outcomes for patients who would benefit from these options.
Physician, Nursing and CMCN credits valid to January 1, 2024

A Closer Look at Recent Real-World and Clinical Trial Data in the Management of HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on the Evolving Role of CDK 4/6 Inhibitors

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2021. The incidence in women in the United States is 1 in 8 (about 13 percent). About 43,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely, and few patients are rendered free of disease. Fortunately for advanced breast cancer patients with HR+/HER2- advanced breast cancer, several new agents, including CDK 4/6 inhibitors, have changed the paradigm in the last 10 years, and recent real-world data has been released that shows the strong efficacy and safety of these options. This webinar series will provide managed care professionals and oncologists with the latest real-world data and strategies in the evolving treatment paradigm. Participants will leave with ability to understand and utilize recent real world and clinical trial data, implement best strategies, tackle first line treatment decisions, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve access and outcomes in patients with HR+/HER2- metastatic breast cancer.
Physician, Nursing and CMCN credits valid to January 1, 2024

What Managed Care Needs to Know About Recent Real-World Evidence and Best Practices for CDK 4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: Utilizing Recent Data for Optimal Decision Making

Adapting to Evolving Treatment Paradigms in Prostate Cancer: New Evidence and Opportunities

Physician, Nursing and CMCN credits valid to March 1, 2023

Evolving Considerations in the Management of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): Expert Strategies on Immune Checkpoint Inhibitors

Head and neck squamous cell carcinoma (HNSCC) represent a heterogeneous group of tumors that originate in the oral cavity, nasal cavity, paranasal sinuses, hypopharynx, oropharynx, nasopharynx, and larynx. It’s estimated that 48,000 new cases are diagnosed annually in the US, with a median age of onset at 60, and is more common in men than women. Historically HNSCC has been associated with tobacco and alcohol use, however, during the past decade, infection with HPV has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in past years, the prognosis for metastatic disease remains poor. Fortunately, novel immunotherapies have recently become available and have shown improved efficacy, tolerability, and safety. Sequencing treatment depends on several factors, to include the stage of the disease, previous treatment, biomarkers, and patient co-morbidities. Combination therapy has also shown promising results however healthcare providers need to realize the implications of managing adverse events and patient adherence to prolong progression free and overall survival, as well as improve patient quality of life.
Physician, Nursing and CMCN credits valid to March 1, 2023

Evolving Considerations in the Treatment and Management of Metastatic Breast Cancer: Expert Strategies for Improved Clinical and Economic Outcomes

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2021. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely, and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with advanced breast cancer, several new agents, including PARP inhibitors, have recently become available. They have shown the ability to improve safety and efficacy outcomes. This activity will provide these healthcare professionals with the appropriate use of new therapies, such as PARP inhibitors, through a shared decision-making approach for the treatment of metastatic breast cancer, and a solid understanding of the mechanism of action of these therapies.
Physician, Nursing and CMCN credits valid to March 1, 2023

Navigating an Increasingly Complex Treatment Paradigm in the Management of Advanced Renal Cell Carcinoma (RCC): A Close Look at New and Emerging Combinations

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. In 2021, it is estimated that there will be approximately 76,080 new cases of kidney cancer, and about 13,780 people will die from the disease. Approximately 16% of patients with RCC will have metastases at diagnosis, and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year survival rate ranging from 5% to 12%, the prognosis for these patients is poor. Fortunately for patients with advanced RCC, several new treatments have recently become available or are undergoing clinical trials giving clinicians new options to improve patient outcomes and quality of life, especially in first-line settings and combination regimens. This activity will
focus on these evolving options, how to integrate them into the treatment paradigm, and how to apply evidence-based data to select appropriate treatment regimens and manage toxicities.
Physician, Nursing and CMCN credits valid to March 1, 2023

Patient-Focused Treatment Decisions in the Management of Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it was expected that there were about 228,820 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 135,720 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Healthcare professionals (HCPs) need to be aware of information regarding tumor-specific diagnosis, expanding treatment options, and supporting data to maximize the care of their patients. With so many effective treatment options becoming available, it is critical to inform medical directors, oncologists and nurses about these agents, and strategies to effectively manage NSCLC patients.
Physician, Nursing and CMCN credits valid to March 1, 2023

Patient-Focused Treatment Decisions in the Management of Metastatic Melanoma: A Close Look at the Evolving Role of Immunotherapy

Melanoma is the most serious type of skin cancer. It will be found in approximately 73,870 people in the US in 2020 according to the National Cancer Institute. While it is the least common amongst skin cancers, it is by far the most deadly, with 9,940 people expected to die in 2020. Both of those numbers have been rising in recent years. Fortunately for patients with metastatic melanoma, significant progress has been made in the treatment of this deadly disease over the past few years, especially in the area of immunotherapies. This webinar on recent advances in the treatment and management of metastatic melanoma will provide attendees with updated treatment strategies, guidelines, and successful evidence-based treatment approaches from recent clinical data.
Physician, Nursing and CMCN credits valid to March 1, 2023

Recent Advances in the Treatment and Management of Ovarian Cancer: Expert Perspectives on the Evolving Role of PARP Inhibitors

There will be an estimated 21,410 new cases of ovarian cancer this year in the United States, and an estimated 13,770 deaths due to ovarian cancer in the US, according to the American Cancer Society. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five-year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Additionally, new indications for these targeted agents offer expanded options in the maintenance setting in varying lines of therapy. This activity on the role of PARP inhibition therapies in the management of ovarian cancer will address this gap in knowledge by providing attendees with updated education on the selection of optimal testing strategies to personalize care, new options for first-line maintenance therapy, reviewing recent clinical data, managing treatment toxicities, the development of evidence-based sequencing and combination strategies, and managed care considerations for these options.
Physician, Nursing and CMCN credits valid to March 1, 2023

Navigating an Increasingly Complex Treatment Paradigm in the Management of HER2-Positive Advanced Breast Cancer: An In-Depth Look at New and Emerging Therapies

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2021. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with advanced breast cancer, several new agents, including PARP inhibitors, have recently become available. They have shown the ability to improve safety and efficacy outcomes. With these options becoming available for the treatment of metastatic breast cancer, it is critical to provide medical directors, oncologists, practicing physicians and others on the interprofessional management team with updated clinical data and strategies on the changing treatment paradigm, with the ultimate goal of improving patient outcomes.

Physician, Nursing and CMCN credits valid to March 1, 2023

A Closer Look at Recent Data and Guideline Updates in CLL: Expert Perspectives on the Evolving Role of BTK Inhibitors and Combination Therapy

Novel Treatment Advances and Approaches in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Expert Perspectives on the Evolving Role of Immunotherapy

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it was expected that there were about 222,500 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 155,870 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. Recent clinical data have demonstrated that NSCLC is a very heterogeneous disease. However, as more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Fortunately for patients with metastatic NSCLC, immune checkpoint inhibitors have become available in recent years, with more coming soon, that have showed improved efficacy, safety and outcomes, especially in patients with high levels of PD-L1 expression.

As more immunotherapies are becoming available, the treatment paradigm has grown expansive, making it difficult for clinicians and managed care professionals to make the appropriate decisions based on recent clinical data and guidelines. In this program on NSCLC, medical directors, oncologists, and nurses will learn about the optimal use of current and emerging immunotherapy treatment options and new options that are just becoming available, ultimately helping patients achieve a greater quality of life and improved clinical and economic outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2023

Novel Treatment Advances and Approaches in the Management of Advanced Non-Small Cell Lung
Cancer (NSCLC): Expert Perspectives on the Evolving Role of Immunotherapy

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it was expected that there were about 222,500 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 155,870 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. Recent clinical data have demonstrated that NSCLC is a very heterogeneous disease. However, as more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Fortunately for patients with metastatic NSCLC, immune checkpoint inhibitors have become available in recent years, with more coming soon, that have showed improved efficacy, safety and outcomes, especially in patients with high levels of PD-L1 expression.

Comparative Effectiveness and Coordinated Care in Advanced Non-Small Cell Lung Cancer (NSCLC): Managed Care Considerations on Immune Checkpoint Inhibitors

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it was expected that there were about 222,500 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 155,870 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. Recent clinical data have demonstrated that NSCLC is a very heterogeneous disease. However, as more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Fortunately for patients with metastatic NSCLC, immune checkpoint inhibitors have become available in recent years, with more coming soon, that have showed improved efficacy, safety and outcomes, especially in patients with high levels of PD-L1 expression.

Leveraging Immunotherapy in Women’s Cancers: Expert Perspectives on Current Evidence and Practical Guidance in Cervical and Endometrial Cancers

Although cervical and endometrial cancers are associated with high rates of positive clinical outcomes when detected early enough, many cases are not detected until they have reached an advanced stage. The management of patients with advanced/metastatic disease remains an important clinical and economic challenge. Pursuit of treatment options that may help to improve clinical efficacy and limit treatment-associated adverse events is an active area of investigation, with several options showing promise in recent studies. An understanding of the mechanisms underlying the development of these diseases has helped to inform new approaches to clinical management, which may improve outcomes for your patients.
Physician, Nursing and CMCN credits valid to August 1, 2023

Copyright permissions

To the best of our knowledge permissions for use of any copyright materials was received by each individual presenter. NAMCP/AAMCN does receive permissions to record, transcribe and publish materials (slides and audio) from each speaker. These permissions are on file at NAMCP headquarters.

For more information contact Jeremy Williams at 804-527-1905 or jwilliams@namcp.org.

Disclaimer

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.